Biogen Writes Off Aduhelm Stock
Biogen has written off its remaining Aduhelm inventory in a filing to the Securities and Exchange Commission (SEC) filing. The company declared that its stock of the failed Alzheimer’s drug was functionally worthless, in contrast with a $233 million valuation towards the end of 2021. The remaining stock will be available to patients that are already using the drug, such as those in clinical trials.
Biogen Ends Aduhelm Study Due to Medicare Restrictions
Biogen has ended its observational ICARE AD real-world data (RWD) trial for Aduhelm, another in a long series of setbacks [...]
Biogen CEO Michel Vounatsos to Step Down After Aduhelm Controversies
Biogen has announced that Michel Vounatsos will resign from his position as CEO. This decision comes amidst layoffs and restructuring [...]
Biogen Alzheimer’s Drug Pulled from European Application Process
Following a rocky series of setbacks in Europe and abroad, Biogen has backed out of the application process in Europe [...]
The Future of Aduhelm after CMS Stands its Ground
The Centers for Medicare and Medicaid Services (CMS) have held firm with their previous draft guidance to only fund Aduhelm [...]
Biogen Starts Real-World Data Network for Neurological Disease Therapeutics
The makers of Aduhelm have set up the Clinical Data Research Network (CRDN), a real-world evidence (RWE) database with data [...]
Access to Alzheimer’s Drugs in Question Due to Medicare Draft Coverage
The draft guidance released by the Centers for Medicare and Medicaid Services (CMS) regarding coverage for the Alzheimer’s drug Aduhelm [...]
Alzheimer’s Advocates Ask US Govt to Approve Aduhelm Medicare Reimbursement
In response to Medicare’s decision to only cover the Alzheimer’s drug Aduhelm in clinical trials, patient advocacy groups have begun [...]
Biogen Will Ensure Increased Diversity in Aduhelm Trials
Biogen has just promised that Black and Latinx people will account for at least 18% of participants in Aduhelm’s mandated [...]
Aduhelm Sparks Discourse about Equity in Alzheimer’s Care
The debate over systemic inequity in Alzheimer’s treatment has been stirred once again by Medicare’s proposal to only cover Aduhelm, [...]
Draft Ruling from CMS Suggests Narrow Coverage for Aduhelm
The Centers for Medicare & Medicaid Services (CMS) have released a draft ruling indicating it will only cover Biogen’s Alzheimer’s [...]
Experts in Alzheimer’s Recommend Accelerated Withdrawal for Aduhelm
A group of medical professors and expert researchers in Alzheimer’s disease have asked the FDA to quickly withdraw their approval [...]
Insurers Refuse to Pay for New Alzheimer’s Drug Without Evidence of Efficacy
Twenty-five major insurers will not pay for Biogen’s Alzheimer’s drug Aduhelm without further proof of efficacy, according to results from [...]
Biogen Reports Low Aduhelm Sales Amid Medicare Uncertainty
Biogen reported low sales of Alzheimer’s drug Aduhelm. Although the Centers for Medicare and Medicaid (CMS) are unable to negotiate [...]
CMMI Director Discusses Aduhelm Coverage
Center for Medicare and Medicaid Innovation (CMMI) Director Elizabeth Fowler recently discussed Biogen’s Aduhelm drug. She noted that Congress first needs [...]
MedPAC Talks Value-Based Healthcare and International Reference Pricing As Aduhelm Cost Sounds Alarms
The Medicare Payment Advisory Commission (MedPAC) is considering a series of measures that would reduce healthcare costs, including international reference pricing [...]
Prescription Drug Pricing Reform Could Mean Discounts on AAP Drugs Pending Clinical Proof
As multidisciplinary stakeholders consider how to reform the prescription drug pricing structure, one recent proposal is gaining traction. Drugs pushed [...]
Should the FDA Follow Advisory Committee Votes in Drug Approvals?
A recent survey requested feedback from advisory committee members. Most respondents thought that a thumbs down from committee members should [...]
Pfizer Heart Failure Medication Lawsuit Ruling Could Broadly Impact Medicare, Lead to Expensive Aduhelm Coverage
Pfizer is seeking legal backing for its plan to pay healthcare costs for Medicare patients taking one of its pricy [...]
Vanderbilt and Stanford Professors Discuss 2021 Drug Pricing Reform in JAMA Article, Note Power of Value Assessments and Medicare Negotiation During COVID-19 Pandemic
Dr. Stacie Dusetzina of Vanderbilt University School of Medicine and Dr. Michelle Mello of Stanford Law School and Stanford School [...]